Document is current

Article History

Received: 29 December 2025

Accepted: 30 January 2026

First Online: 7 February 2026

Declarations

:

: The data for this manuscript were collected from the NCT04427384 Registry Study. Although non-interventional in design, the study was reviewed and approved by the WCG-Connexus Institutional Review Board (IRB approval #20201634). Informed consent for patients in the NCT04427384 Registry Study was obtained by investigators in compliance with applicable regulations and following best clinical practice.

: M.J.S, C.J.S., S.H., L.S., S.L., C.C.C., and M.S.P. are consultants for GT Medical Technologies, Inc. I.L. is a consultant for Medtronic Inc. and Monteris. C.C.C. is a consultant for Medtronic Inc. and Everfront. L.S. receives research and travel support from GT Medical Technologies, Inc. E.C.P. is the owner of Biostatistical Consulting Inc., which has a consulting agreement with GT Medical Technologies, Inc. R.W. receiving funding from an Elekta research grant. R.K. reports clinical trial support from Medtronic Inc., Blue Earth Diagnostics, Ltd, Novocure Inc., GT Medical Technologies, Inc., AstraZeneca, Exelixis, Viewray Inc., Brainlab, Cantex Pharmaceuticals Inc., Ion Beam Applications, and Kazia Therapeutics Inc.; consulting fees from Kazia Therapeutics Inc., Elekta AB, Viewray Inc., Castle Biosciences, NovoCure Inc., Telix Pharmaceuticals, and GT Medical Technologies, Inc.; speaker’s fees from Elekta AB, Accuray Inc., NovoCure Inc., Viewray Inc., Elsevier Inc., BrainLab, Peerview Institute for Medical Education, and Ion Beam Applications; travel support from Elekta AB, NovoCure Inc., Peerview Institute for Medical Education, Viewray Inc., BrainLab, Zap Surgical Systems, Inc., and GT Medical Technologies, Inc. He has participated in advisory boards for Viewray Inc., GT Medical Technologies, Inc., Insightec Ltd, and Plus Therapeutics, Inc. M.A.G., D.B., and S.P. are employees and stockholders of GT Medical Technologies, Inc. S.L. holds shares in Remedy Pharmaceuticals, Martin Pharmaceuticals, Woolsley Pharmaceuticals, Cytonics Corporation, and 20/20 Gene Systems. The remaining authors declare that they have no conflicts of interest related to the preparation and submission of this manuscript, nor any other relevant disclosures.